References
Thesis
Author
Antonio Longo
1. Associazione Italiana per lo Studio del Dolore, XXX convegno, Luglio 2007.
2. Manninon RJ., Woolf CJ., The Clinical Journal of Pain. 2000.
3. Boyd PB., Mersket H., A Note on the Description of Pain and its Causes, Pain. 1978; S(1): 1-3.
4. Treede RD., Peripheral Acute Pain Mechanism, Ann. Med. 27, 213-216 (1995).
5. Melzack R., Wall PD., Pain Mechanism: a new theory, Scince, 1965; 150: 171-9.
6. Hunt SP., Mantyh PW., The Molecular Dynamics of Pain Control, Nature review, 2, 85, 2001.
7. Mogil JS., Pasternak GW., The Molecular Behavioral Pharmacology of Orphanin (nociceptin peptides), Pharmacological Review, 53/3, 381, 2001.
8. Evans CJ., Keith DE. Jr, Morrison H. et al., Cloning of a d-opioid Receptor by Functional Expression, Science.1992; 258: 1952-1955.
9. Chen Y., Mastek A., Liu J. et al., Molecularr Cloning and Functional Expression of mu-opioid Receptor from Rat Brain, Mol. Pharmacol. 1993; 44: 8-12.
10. Kieffer BL., Befort K., Galeriaux-Ruff C. et al., The d-opioid receptor: Expression Cloning and Pharmacological Characterisation, Proc. Nati. Acad. Usa 89, 12 048- 12 052.
11. World Health Organization, Cancer Pain Relief with a Guide to Opioid Availability, 1996.
12. Doyle D., Hanks GWC., MacDonald N. et al., Management of Pain, Oxford Textbook of Palliative, Oxford University Press, 1998.
13. Max MB., Payne R., Edwards WT. et al., Principles of Analgesic Use in the Treatment of Acute Pain and Cancer Pain, 4th Ed. Glenview, IL: American Pain Society; 1999.
14. Rang, Dale, Ritter, Moor, Farmacologia 3rd Ed., Casa Editrice Ambrosiana.
15. Silverman: The Organic Chemistry of Drug Design and Drug Action,2nd Ed., Academic Press
16. Williams, Lemke: Foey's Principi di chimica Farmaceutica, 4th Ed., Piccin.
17. Artico M., Lezioni di Chimica Farmaceutica e Tossicologica II, Vol. 1-3, Edizioni CISU.
18. Hollander D., Gastrointestinal Complication of Nonsteroidal Antiinflammatory Drugs: Prophilactic and Therapeutic Strategies, Am. J Med. 1994; 96: 274-281.
19. Nice, Guidance on the Use of Cyclo-oxygenase (CoX) II Selective Inhibitors, Colocoxib, Rofecoxib, Meloxicam and Etodolac for Osteoarthitis and Reumatoid Arthritis, Review May 2004.
20. Katzung BG., Farmacologia Generale e Clinica, Piccin Nuova Libreria s.p.a. 2006.
21. Reisine T., Pasternak G., Opioid Analgesics and Antagonists, Pharmacologic basis of Therapeutics, 9th Ed., 1996; 531-555.
22. Pasero C., Portenoy RK., Mc Cafey M., Opioid Analgesics Pain. Pain Clinical Manual 2nd Ed. 1999; 161-299.
23. Miyoshi HR., Lecrbaba SG., Systemic Opioid Analgesics, Bonica's Management of Pain 3rd Ed. 2001: 1682-1709.
24. Rang, Dale, Ritter, Moor, Farmacologia 3rd Ed., Casa Editrice Ambrosiana.
25. Silverman: The Organic Chemistry of Drug Design and Drug Action,2nd Ed., Academic Press
26. Williams, Lemke: Foey's Principi di chimica Farmaceutica, 4th Ed., Piccin.
27. Artico M., Lezioni di Chimica Farmaceutica e Tossicologica II, Vol. 1-3, Edizioni CISU.
28. Portenoy RK:, Mc Cafferty M., Adiuvant Analgesics, Pain Clinical Manual 2nd Ed. 1999: 300-361.
29. Carter GT., Galer BS., Adiuvances in the Management of Neuropathic Pain, Phys Med Rehabil Clin N. Am. 2001; 12(2): 447-459
30. Bonezzi C., Demartin L., Treatment Options in Posterpethic Neuralgia, ACTA Neuronal Scand Suppl. 1999; 173: 25-35; discussion 48-92 review.
31. Watson CP., The Treatment of Neuropathic Pain: Antidepressant and Opioids, Clin J Pain. 2000; 16(suppl 2): 549- 555 review.
32. Chassman AH., Bigger JT., Cardiovascular effects of Therapeutic Doses of Tricyclic Antidepessant, Arch General Psychiatry. 1981; 38: 815-820.
33. Tremont-Luktas IW, Megeff C., Backonja MM., Anticonvulsants for Neuropathic Pain Syndromes: Mechanism of Action and Place in Therapy, Drugs. 200; 60(s): 1029-1052.
34. McQuay H., Carroll D., Jadad AR. et al., Anticonvulsant Drugs for Management of Pain, A systemic Reviw BMJ. 1995; 311: 1047-1052
35. Watanab S. et al., Corticosteroids as Adjuvant Analgesics, J Pain Sympt Manage.1994; 9: 422.
36. Fleiisc H., The Role of Bisphosphonates in Breast Cancer: Development of Bisphosphonates, Breast Cancer res. 2002; 4: 30-34.
37. Bouckomas AJ., Litmare RE., Clonazepam in the Treatment of Neuralgic Pain Syndrome, Psycomatics. 1995; 26(12) : 933-936.
38. Serrao JM., Mars RL., Morley SJ. et al., Intratecal Midazolam for Treatmentpf Cronic Mechanical Low Back Pain: a controlled comparison with epidural steroid in a pilot study. Pain. 1992; 48(1) : 5-12.
39. Torta R., Lacerenza M., La Depressione nelle malattie neurologiche: depressione e dolore, UTET Periodici, Milano 2002.
40. Van Sickle Md. et al., Identification and Functional Chracterization of Brainstem Cannabinoid CB2 Receptor, Science. 2005; 310(5746): 329-352.
41. Munro S., Thomas KL., abu-Shaar M., Molecular Characterization of a Peripheral Receptor of Cannabionoids, Nature. 1993; 365: 61-65.
42. Howlett AC., The Cannabinoid Receptor. Prostaglandins other Lipid Mediat. 2002; 68-69: 619-631.
43. Felder C., Glass M., Annu, Cannabioid Receptor and their Endogenous Agonists, Rev Pharmacol Toxicol 1998; 38: 179-200.
44. Darmani NA., Jhonson JC., Central and Peripheral Mechanism Contribute to the Antiemetic Action of ?-9-tetraidrocannabinolo, European Journal of Pharmacology. 2004, 488: 201-212.
45. Backer D. et al., Endocannabinoids control spasticy in a Multiple Sclerosis model, The FASEB Journal. 2001; 15: 300-302.
46. Glass M., The Role of Cannabinoids in Neurodegenerative disease, Prog Neuro-Psychopharmacol & Biol. Psychat. 2001; 25: 743-765.
47. Wilson RI., Nicoll RA., Endocannabinoid Signaling in the Brain, Science. 2002; 296: 678-682.
48. Regio Decreto del 27 Luglio 1934, n. 1265 (TULS)
49. Ufficio Centrale degli Stupefacenti, Ministero della Salute
2. Manninon RJ., Woolf CJ., The Clinical Journal of Pain. 2000.
3. Boyd PB., Mersket H., A Note on the Description of Pain and its Causes, Pain. 1978; S(1): 1-3.
4. Treede RD., Peripheral Acute Pain Mechanism, Ann. Med. 27, 213-216 (1995).
5. Melzack R., Wall PD., Pain Mechanism: a new theory, Scince, 1965; 150: 171-9.
6. Hunt SP., Mantyh PW., The Molecular Dynamics of Pain Control, Nature review, 2, 85, 2001.
7. Mogil JS., Pasternak GW., The Molecular Behavioral Pharmacology of Orphanin (nociceptin peptides), Pharmacological Review, 53/3, 381, 2001.
8. Evans CJ., Keith DE. Jr, Morrison H. et al., Cloning of a d-opioid Receptor by Functional Expression, Science.1992; 258: 1952-1955.
9. Chen Y., Mastek A., Liu J. et al., Molecularr Cloning and Functional Expression of mu-opioid Receptor from Rat Brain, Mol. Pharmacol. 1993; 44: 8-12.
10. Kieffer BL., Befort K., Galeriaux-Ruff C. et al., The d-opioid receptor: Expression Cloning and Pharmacological Characterisation, Proc. Nati. Acad. Usa 89, 12 048- 12 052.
11. World Health Organization, Cancer Pain Relief with a Guide to Opioid Availability, 1996.
12. Doyle D., Hanks GWC., MacDonald N. et al., Management of Pain, Oxford Textbook of Palliative, Oxford University Press, 1998.
13. Max MB., Payne R., Edwards WT. et al., Principles of Analgesic Use in the Treatment of Acute Pain and Cancer Pain, 4th Ed. Glenview, IL: American Pain Society; 1999.
14. Rang, Dale, Ritter, Moor, Farmacologia 3rd Ed., Casa Editrice Ambrosiana.
15. Silverman: The Organic Chemistry of Drug Design and Drug Action,2nd Ed., Academic Press
16. Williams, Lemke: Foey's Principi di chimica Farmaceutica, 4th Ed., Piccin.
17. Artico M., Lezioni di Chimica Farmaceutica e Tossicologica II, Vol. 1-3, Edizioni CISU.
18. Hollander D., Gastrointestinal Complication of Nonsteroidal Antiinflammatory Drugs: Prophilactic and Therapeutic Strategies, Am. J Med. 1994; 96: 274-281.
19. Nice, Guidance on the Use of Cyclo-oxygenase (CoX) II Selective Inhibitors, Colocoxib, Rofecoxib, Meloxicam and Etodolac for Osteoarthitis and Reumatoid Arthritis, Review May 2004.
20. Katzung BG., Farmacologia Generale e Clinica, Piccin Nuova Libreria s.p.a. 2006.
21. Reisine T., Pasternak G., Opioid Analgesics and Antagonists, Pharmacologic basis of Therapeutics, 9th Ed., 1996; 531-555.
22. Pasero C., Portenoy RK., Mc Cafey M., Opioid Analgesics Pain. Pain Clinical Manual 2nd Ed. 1999; 161-299.
23. Miyoshi HR., Lecrbaba SG., Systemic Opioid Analgesics, Bonica's Management of Pain 3rd Ed. 2001: 1682-1709.
24. Rang, Dale, Ritter, Moor, Farmacologia 3rd Ed., Casa Editrice Ambrosiana.
25. Silverman: The Organic Chemistry of Drug Design and Drug Action,2nd Ed., Academic Press
26. Williams, Lemke: Foey's Principi di chimica Farmaceutica, 4th Ed., Piccin.
27. Artico M., Lezioni di Chimica Farmaceutica e Tossicologica II, Vol. 1-3, Edizioni CISU.
28. Portenoy RK:, Mc Cafferty M., Adiuvant Analgesics, Pain Clinical Manual 2nd Ed. 1999: 300-361.
29. Carter GT., Galer BS., Adiuvances in the Management of Neuropathic Pain, Phys Med Rehabil Clin N. Am. 2001; 12(2): 447-459
30. Bonezzi C., Demartin L., Treatment Options in Posterpethic Neuralgia, ACTA Neuronal Scand Suppl. 1999; 173: 25-35; discussion 48-92 review.
31. Watson CP., The Treatment of Neuropathic Pain: Antidepressant and Opioids, Clin J Pain. 2000; 16(suppl 2): 549- 555 review.
32. Chassman AH., Bigger JT., Cardiovascular effects of Therapeutic Doses of Tricyclic Antidepessant, Arch General Psychiatry. 1981; 38: 815-820.
33. Tremont-Luktas IW, Megeff C., Backonja MM., Anticonvulsants for Neuropathic Pain Syndromes: Mechanism of Action and Place in Therapy, Drugs. 200; 60(s): 1029-1052.
34. McQuay H., Carroll D., Jadad AR. et al., Anticonvulsant Drugs for Management of Pain, A systemic Reviw BMJ. 1995; 311: 1047-1052
35. Watanab S. et al., Corticosteroids as Adjuvant Analgesics, J Pain Sympt Manage.1994; 9: 422.
36. Fleiisc H., The Role of Bisphosphonates in Breast Cancer: Development of Bisphosphonates, Breast Cancer res. 2002; 4: 30-34.
37. Bouckomas AJ., Litmare RE., Clonazepam in the Treatment of Neuralgic Pain Syndrome, Psycomatics. 1995; 26(12) : 933-936.
38. Serrao JM., Mars RL., Morley SJ. et al., Intratecal Midazolam for Treatmentpf Cronic Mechanical Low Back Pain: a controlled comparison with epidural steroid in a pilot study. Pain. 1992; 48(1) : 5-12.
39. Torta R., Lacerenza M., La Depressione nelle malattie neurologiche: depressione e dolore, UTET Periodici, Milano 2002.
40. Van Sickle Md. et al., Identification and Functional Chracterization of Brainstem Cannabinoid CB2 Receptor, Science. 2005; 310(5746): 329-352.
41. Munro S., Thomas KL., abu-Shaar M., Molecular Characterization of a Peripheral Receptor of Cannabionoids, Nature. 1993; 365: 61-65.
42. Howlett AC., The Cannabinoid Receptor. Prostaglandins other Lipid Mediat. 2002; 68-69: 619-631.
43. Felder C., Glass M., Annu, Cannabioid Receptor and their Endogenous Agonists, Rev Pharmacol Toxicol 1998; 38: 179-200.
44. Darmani NA., Jhonson JC., Central and Peripheral Mechanism Contribute to the Antiemetic Action of ?-9-tetraidrocannabinolo, European Journal of Pharmacology. 2004, 488: 201-212.
45. Backer D. et al., Endocannabinoids control spasticy in a Multiple Sclerosis model, The FASEB Journal. 2001; 15: 300-302.
46. Glass M., The Role of Cannabinoids in Neurodegenerative disease, Prog Neuro-Psychopharmacol & Biol. Psychat. 2001; 25: 743-765.
47. Wilson RI., Nicoll RA., Endocannabinoid Signaling in the Brain, Science. 2002; 296: 678-682.
48. Regio Decreto del 27 Luglio 1934, n. 1265 (TULS)
49. Ufficio Centrale degli Stupefacenti, Ministero della Salute